Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | GAK | O14976 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282202 | 0.90 | DGAT1 (0.33) | AOC3DGAT1KCNH2 | |
| SCHEMBL1282345 | 0.89 | MEN1 (0.34) | MAPTAOC3DGAT1KCNH2 | |
| SCHEMBL1282442 | 0.89 | DGAT1 (0.30) | PTPN11DGAT1KCNH2 | |
| SCHEMBL1282894 | 0.88 | PTPN11 (0.35) | PTPN11GAKMAPTADORA2AADORA2B | |
| SCHEMBL1282931 | 0.88 | PARP1 (0.35) | PTPN11 | |
| SCHEMBL1283397 | 0.88 | PTPN11 (0.33) | PTPN11KITSSTR5 | |
| SCHEMBL1283013 | 0.86 | — | — | |
| SCHEMBL1282848 | 0.86 | DGAT1 (0.31) | DGAT1KCNH2 | |
| SCHEMBL1283194 | 0.86 | PRKCA (0.34) | PTPN11SSTR5 | |
| SCHEMBL1282268 | 0.86 | DGAT1 (0.31) | DGAT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | claimed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | PTPN11 4067/4885KIT 4400/4885GAK 3777/4885 |
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | PTPN11 2315/4885KIT 4808/4885GAK 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.